CYCN

+ Watchlist + Portfolio

Cyclerion Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.52
52-Week Range: $2.82 – $59.36
Market Cap: $15.73M
P/E (TTM): —
EPS (TTM): -11.62
Dividend Yield: —

Advanced Metrics

Price/Book: 2.81
PEG Ratio: —
Return on Equity: -98.22%
Return on Assets: -52.33%
Gross Margin: 15.95%
Operating Margin: -359.16%
Profit Margin: 0.00%
Current Ratio: 0.82
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-2.08M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $14.09M

CYCN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$297.00K	$0.00	$2.00M	$2.07M
Research & Development	$5.98M	$1.51M	$286.00K	$959.00K
Selling, General & Admin	$12.86M	$8.13M	$5.34M	$6.09M
Operating Expenses	$18.84M	$9.65M	$5.63M	$7.05M
Operating Income	-$18.54M	-$9.65M	-$3.63M	-$4.97M
EBITDA	-$18.48M	-$9.65M	-$3.63M	-$4.97M
Pretax Income	-$18.25M	-$12.59M	-$3.06M	-$3.53M
Net Income	-$44.08M	-$5.26M	-$3.06M	-$3.53M
Diluted EPS	-20.28	-2.25	-1.21	-1.11
Diluted Shares	2.17M	2.34M	2.52M	3.18M

CYCN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.38M	$7.57M	$3.23M	$3.24M
Receivables	$96.00K	$0.00	$556.00K	$1.00M
Current Assets	$14.82M	$8.02M	$4.22M	$4.63M
Total Assets	$18.08M	$13.37M	$9.57M	$9.98M
Current Liabilities	$7.63M	$2.09M	$725.00K	$900.00K
Total Liabilities	$7.63M	$2.09M	$725.00K	$900.00K
Retained Earnings	-$259.15M	-$264.42M	-$267.49M	-$271.02M
Shareholders' Equity	$10.45M	$11.29M	$8.85M	$9.09M
Working Capital	$7.19M	$5.94M	$3.50M	$3.73M

CYCN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$40.61M	-$21.25M	-$4.33M	-$3.31M
Free Cash Flow	-$40.61M	-$21.25M	-$4.33M	-$3.31M
Depreciation & Amortisation	$65.00K	$0.00	—	—
Stock-Based Compensation	$6.25M	$1.07M	$625.00K	$441.00K
Investing Cash Flow	$0.00	$10.40M	$0.00	—
Financing Cash Flow	$29.00K	$5.02M	$0.00	$3.32M
Share Repurchases	—	—	$0.00	-$130.00K
Net Change in Cash	-$40.58M	-$5.82M	-$4.33M	$8.00K

CYCN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$81.00K	$93.00K	$875.00K	$1.02M	$0.00	$0.00
Research & Development	$36.00K	$56.00K	$348.00K	$519.00K	$730.00K	$0.00
Selling, General & Admin	$1.50M	$1.71M	$1.53M	$1.34M	$2.48M	$1.77M
Operating Expenses	$1.54M	$1.76M	$1.88M	$1.86M	$3.21M	$1.77M
Operating Income	-$1.46M	-$1.67M	-$1.01M	-$838.00K	-$3.21M	-$1.77M
EBITDA	-$1.46M	-$1.67M	-$1.01M	-$838.00K	-$3.21M	-$1.77M
Pretax Income	-$1.43M	-$324.00K	-$976.00K	-$799.00K	-$3.18M	-$1.75M
Net Income	-$1.43M	-$324.00K	-$976.00K	-$799.00K	-$3.18M	-$1.75M
Diluted EPS	-0.56	-0.11	-0.30	—	-0.76	-0.41
Diluted Shares	2.56M	3.07M	3.23M	—	4.21M	4.25M

CYCN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.64M	$3.01M	$4.57M	$3.24M	$2.82M	$1.39M
Receivables	$581.00K	$525.00K	$100.00K	$1.00M	$0.00	$0.00
Current Assets	$4.50M	$4.02M	$5.07M	$4.63M	$3.09M	$1.51M
Total Assets	$9.85M	$9.37M	$10.41M	$9.98M	$8.51M	$6.93M
Current Liabilities	$1.07M	$800.00K	$877.00K	$900.00K	$1.71M	$1.84M
Total Liabilities	$1.07M	$800.00K	$877.00K	$900.00K	$1.71M	$1.84M
Retained Earnings	-$268.92M	-$269.25M	-$270.22M	-$271.02M	-$274.20M	-$275.95M
Shareholders' Equity	$8.78M	$8.57M	$9.54M	$9.09M	$6.79M	$5.09M
Working Capital	$3.43M	$3.22M	$4.19M	$3.73M	$1.38M	-$329.00K

CYCN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$968.00K	-$503.00K	-$264.00K	-$1.58M	-$1.18M	-$1.43M
Capital Expenditure	—	—	—	—	-$66.00K	—
Free Cash Flow	-$968.00K	-$503.00K	-$264.00K	-$1.58M	-$1.24M	-$1.43M
Stock-Based Compensation	$114.00K	$114.00K	$118.00K	$95.00K	$58.00K	$51.00K
Investing Cash Flow	$0.00	$0.00	—	—	-$66.00K	$0.00
Financing Cash Flow	$1.38M	-$130.00K	$1.83M	$251.00K	$825.00K	$0.00
Net Change in Cash	$407.00K	-$633.00K	$1.56M	-$1.33M	-$417.00K	-$1.43M

Market Snapshot

About

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious central nervous system and peripheral diseases. The company's lead programs target soluble guanylate cyclase (sGC), an enzyme involved in multiple disease pathways. Cyclerion's pipeline includes product candidates for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), serious CNS diseases, and other conditions. The company leverages its sGC platform to develop novel therapeutic approaches for diseases with significant unmet medical needs.